Clinical trial NCT04830735: Dasatinib for the Treatment of Moderate and Severe COVID-19
Official title: A Phase II Randomized Double-Blind Trial of Dasatinib Modulation of Hyperinflammation in Moderate and Severe Patients With COVID-19
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Symptomatic COVID-19 Infection Laboratory-Confirmed
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2021-04-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This phase II trial investigates how well dasatinib works in treating patients with moderate and severe COVID-19. Dasatinib is a drug used to treat chronic leukemia which may help reduce the strong inflammation caused by COVID-19 that can damage the lungs or other organs.

Detailed description: PRIMARY OBJECTIVES:

I. To determine the proportion of patients requiring intubation/ventilator support, requiring rescue with tocilizumab, or dying.

II. To determine 1 month survival.

SECONDARY OBJECTIVES:

I. To estimate the safety and tolerability of dasatinib anhydrous (dasatinib) in the setting of COVID-19 infection.

II. To determine change in C-reactive protein (CRP) levels after starting therapy.

III. To document activity of dasatinib in lessening cytokine release syndrome (CRS) and sequential organ failure assessment (SOFA) score.

EXPLORATORY OBJECTIVES:

I. Interleukin-6 /cytokine assay weekly on treatment protocol. II. Ferritin levels at study entry and every (q) 2 days on treatment protocol. III. D-dimer levels at study entry and q 2 days on treatment protocol.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive dasatinib anhydrous orally (PO) once daily (QD) for 14 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 28 days.

Eligibility criteria: Inclusion Criteria:

* Patients must have laboratory test proven COVID19 and symptomatic disease requiring hospitalization: virological diagnosis of Sars-CoV2 infection (polymerase chain reaction \[PCR\]) within 14 days
* Able to sign informed consent for participation in the study
* Subject is hospitalized with one or more of the following:

  * Moderate disease: peripheral capillary oxygen saturation (SpO2) \>= 93% on room air with one of the following risk factors for developing severe disease: age \>= 60 years, history of hypertension, diabetes mellitus, cardiac disease, chronic lung disease, obesity (calculated body mass index \[BMI\] \>= 30 kg/m\^2), and cardiovascular disease, clinical and/or radiological evidence of chest involvement, CRP \> 2X upper limit of normal, doubling of CRP in 24 hours where chest findings and CRP elevation not explained by other underlying disease.

After the first interim analysis, we may allow enrollment of severe disease COVID infected patients if safety and efficacy analysis appears favorable:

* Severe disease:

  * Respiratory rate \>= 30 breaths/ minute (min)
  * SpO2 \< 93% while breathing room air
  * Partial pressure of oxygen measurement (PaO2)/fraction of inspired oxygen (FiO2) =\< 300 mmHg

    * Absolute neutrophil count (ANC) \> 1000 (baseline blood counts)
    * Platelets \> 50,000 / mmc (baseline blood counts)
    * Alanine aminotransferase/aspartate aminotransferase (ALT/AST) \< 5 times the upper limit of the normality
    * Total bilirubin \< 3 x institutional upper limit of normal (IULN)
    * Creatinine \< 2.5 times the upper limit of the normality
    * Azithromycin allowed but if on both drugs patient should be on constant cardiovascular (CV) monitoring
    * Subject must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessment/procedures being conducted
    * Subject is willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

* Pleural effusion \> grade 2 evident on chest x-ray (CXR) or chest computed tomography (CT)
* Intubation/mechanical ventilation
* Known hypersensitivity to dasatinib
* Patient being treated with immunomodulators or anti-rejection drugs
* Known active infections or other clinical condition that contraindicate dasatinib and cannot be treated or solved according to the judgement of the clinician
* ALT/AST \> 5 times the upper limit of the normality
* Total bilirubin \> 3 x IULN
* Neutrophils \< 1000 / mmc unless; platelets \< 50,000 / mmc

Primary outcomes:
measure: Proportion of participants requiring invasive mechanical ventilation, requiring tocilizumab or dying
timeFrame: Up to 28 days
Secondary outcomes:
measure: Absolute lymphocyte count
timeFrame: Baseline, during treatment (day 1-14) up to 1 month
measure: CRP (C-reactive protein) level
timeFrame: Baseline, during treatment (day 1-14) up to 1 month
measure: Change of the SOFA (Sequential Organ Failure Assessment)
timeFrame: Baseline, during treatment (day 1-14) up to 1 month
measure: Number of participants with treatment-related side effects
timeFrame: During treatment and up to 30 days after the last treatment dose
measure: Radiological response
timeFrame: Baseline (optional), after seven days and if clinically indicated(up to 1 month)
measure: Duration of hospitalization
timeFrame: From baseline up to patient's discharge (up to 1 month)
measure: Remission of respiratory symptoms
timeFrame: Up to 1 month
measure: Remission of respiratory symptoms
timeFrame: Up to 1 month
measure: Remission of respiratory symptoms
timeFrame: Up to 1 month
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC / Norris Comprehensive Cancer Center
state: California
Study officials:
affiliation: University of Southern California
name: Ann Mohrbacher, MD
role: PRINCIPAL_INVESTIGATOR
References: